Obesity mediated hypertension and renal dysfunction

Similar documents
Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

In The Name Of God. In The Name Of. EMRI Modeling Group

HSN301 Diet and Disease Entire Note Summary

Obesity and Chronic Kidney. The Catholic University of Korea Cheol Whee Park, M.D.

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME

Metabolic Syndrome in Asians

ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ

Obesity, Metabolic Syndrome, and Diabetes: Making the Connections

JOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY

Cardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen

Blood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD

Blood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

Psoriasis and the metabolic syndrome

Metabolic Syndrome and Chronic Kidney Disease

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

An update on the obesity epidemics in CKD and in ESRD. Does it really matter?

014 Chapter 14 Created: 9:25:14 PM CST

Adrenal gland And Pancreas

Cardiovascular Protection and the RAS

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale

Metabolic syndrome, obesity, diabetes, and theier implications

Doppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75

Obesity related nephropathy in children the need for greater awareness

Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Obesity in the pathogenesis of chronic disease

Metabolic Syndrome: Bad for the Heart and Bad for the Brain? Kristine Yaffe, MD Univ. of California, San Francisco

Role of the fat tissue in the pathogenesis of arterial hypertension and chronic kidney disease

BIOL212 Biochemistry of Disease. Metabolic Disorders - Obesity

Blood pressure control Contin. Reflex Mechanisms. Dr. Hiwa Shafiq

renoprotection therapy goals 208, 209

Dietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components?

FAT. It s Not All That! A Closer Look at the Two Main Types of Fat in Our Bodies: Visceral and Subcutaneous Fat

Managing patients with renal disease

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Prof. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.

Adipose Tissue Dysfunction and Diabetic Cardiovascular Disease

RENAL PHYSIOLOGY. Physiology Unit 4

Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts

DOWNLOAD PDF ADIPOSE TISSUE AND ADIPOKINES IN HEALTH AND DISEASE (NUTRITION AND HEALTH)

Questions? Homework due in lab 6. PreLab #6 HW 15 & 16 (follow directions, 6 points!)

Effects of Exercise and Physical Activity on Diabetes Mellitus and Obesity

SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection

RENAL PHYSIOLOGY WESTMEAD PRIMARY EXAM

BIOH122 Human Biological Science 2

Veins. VENOUS RETURN = PRELOAD = End Diastolic Volume= Blood returning to heart per cardiac cycle (EDV) or per minute (Venous Return)

Effects of growth hormone secretagogue receptor agonist and antagonist in nonobese type 2 diabetic MKR mice

Analysis of AVP functions via V1a and V1b receptors with knockout mice. Akito Tanoue

Fluid and electrolyte balance, imbalance

FAPESP Week /21/2017

Na + /K + interaction in the kidney, blood vessels, brain, and beyond

Cardiovascular System B L O O D V E S S E L S 2

New therapeutic targets for T2DM

β adrenergic blockade, a renal perspective Prof S O McLigeyo

Launch Meeting 3 rd April 2014, Lucas House, Birmingham

Blood Pressure Regulation Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (

Obesity and the kidney

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

The Study of Endothelial Function in CKD and ESRD

Subject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119

SLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota

Tomasz J Guzik. Diabetes, perivascular adipose tissue and inflammation.

Pharmacology - Problem Drill 11: Vasoactive Agents

RENAL PHYSIOLOGY DR.CHARUSHILA RUKADIKAR ASSISTANT PROFESSOR PHYSIOLOGY

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?

METABOLIC SYNDROME IN REPRODUCTIVE FEMALES

Hypertension is a persistent elevation of B.P. above the normal level. Approximately 1 billion people have hypertension

Renal Regulation of Sodium and Volume. Dr. Dave Johnson Associate Professor Dept. Physiology UNECOM

METABOLISM of ADIPOSE TISSUE

Energy balance. Factors affecting energy input. Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Changes in Cardiotrophin-1 and Fibroblast Growth Factor-21 with Weight Loss. Robert Lawrence Bowers

Index. Note: Page numbers of article titles are in boldface type.

ARGININE VASOPRESSIN (AVP)

Regulation of Arterial Blood Pressure 2 George D. Ford, Ph.D.


Diabetic Nephropathy 2009

Getting Ahead of the Curve in the Trouble with Fat

Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes

Establishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group

Chapter 15 Fluid and Acid-Base Balance

BIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1

About OMICS Group Conferences

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center


Males- Western Diet WT KO Age (wks) Females- Western Diet WT KO Age (wks)

THE ROLE OF URIC ACID IN THE PROGRESSION OF CKD Mehmet Kanbay, Istanbul, Turkey

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Faculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease

Glomerular Capillary Blood Pressure

Physio 12 -Summer 02 - Renal Physiology - Page 1

Special Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

The principal functions of the kidneys

Cardiorenal Syndrome

Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009

THE ENDOCANNABINOID SYSTEM IN ADIPOSE TISSUE. Key Points

Prognosis in CKD Can we do anything about it? Rodney D Gilbert

Transcription:

Obesity mediated hypertension and renal dysfunction Gergely Bodor Marion Hervouet Nicky Honnef Mariarosaria Malgadi Julie Robert Tutor: Pr Alina Parvu

Objectives 1. Introduction 2. Renal structural and functional changes in obesity 3. Role of adipocytes mediators in obesity 4. Renin angiotensin aldosterone system in obesity 5. Sympathetic nervous system in obesity 6. Obesity paradox 7. Conclusion

1.Introduction

Overweight and obesity «abnormal or excessive fat accumulation that may impair health» WHO BMI = weight / height² Limits of BMI: OBESITY = HETEROGENOUS CONDITION Others markers of obesity: waist circumference MRI,, cumputed tomography imaging, impedence Tchernof A, Després JP 2014

Abdominal obesity waist circumference > 102 cm (men) > 88 cm (women) Expansion of dysfunctional subcutaneous adipose tissue Ectopic triglyceride storage = Risk factors Tchernof A, Després JP 2014

Visceral obesity Excess intra-abdominal adipose tissue accumulation = main driving force for most of the disorders associated with obesity Tchernof A, Després JP 2014

CKD = Chronic Kidney Disease «The presence of reduced kidney function, or kidney damage, for a period of 3 months or greater» - Chronicity - Constant progression - Systemic consequences Table 2: Stage Description egfr(ml/min/1.73 m2) 1 CKD with normal or increased GFR >90 2 Mild GFR loss 60 89 3 Moderate GFR loss 30 59 4 Severe GFR loss 15 29 5 Kidney failure <15 or dialysis Garland, J. S. (2014).

MS: metabolic syndrome; HBP: high blood pressure; DM: diabetes mellitus; CVD: cardiovascular disease; CKD: chronic kidney disease.

Mechanisms of CKD in obesity Indirect Hypertension Direct Hemodynamic effects Hormonal effects Diabetes Na reabsorption Fatty kidney Compression Compensatory mechanism Increased filtration Vasodilatation Proteinuria ESRD CKD Glomerulosclerosis

The role of adipocytes mediators in obesity

Cells, and adipokines of WAT Preadipocytes Adipocytes Fibroblasts Macrophages Leukocytes Endothel cells Leptin Adiponectin Visfatin Resistin

Resistin Antagonizes insulin Increases Endothelin-1 production Effects of ET-1: Vasoconstrictor tone Nitric oxide bioavailability In CKD Endothelial dysfunction GFR Briffa JF; 2013

Visfatin TNF-α, IL-6, IL-1B ROS Renin and Angiotensinogen mrna Inflammation Oxydative stress renal pathology GFR Sommer G; 2008

Adiponectin Effects: Cardioprotective: Insulin sensitivity ROS production Acivates AMP activated protein kinase In podocytes: downregulation of NADPH oxidase Adiponectin levels are correlated: Negatively: Body fat %, Type-2 diabetes, Insulin resistance, Hypertension Positively: Albuminuria, CKD, Type-2 diabetes Sweiss N; 2014

Leptin SNS activation Hall JE; 2005

Hall JE; 2005 Leptin-receptor metiated pathways

Leptin in the kidneys ROS, ET-1 HT,Endothelial dysfunction glomerulosclerosis TGF-β1 EC matrix expansion Alix PM; 2014

nflamation of WAT in obesity Overstretched adipocytes TNF-α, IL-6, MCP-1 Systemic subclinical inflammatory response

OBESITY INFLAMMATION OXIDATIVE STRESS CKD

Renin angiotensin aldosterone system in obesity

Blood pressure Juxtaglomerular cells PHYSIOLOGICALLY Angiotensinogen Cardio-pulmonar baroreceptor (SNS) Macula densa renin ACE Angiotensin I Angiotensin II Aldosterone Arteriolar Vasoconstriction Vascular tone ENaC and Na/K pump Na reabsorption Fluid volume Blood pressure

Adipose tissue VISCERAL OBESITY Production of bioactives molecules RAAS receptors and components RAAS activation SNS angiotensinogen Adipose tissue differenciation and proliferation Aldosterone Activation of mineralocorticoides and glucocorticoides receptors Blood Pressure 1 Garland (2014) 2 Kurukulasurya (2011)

Obesity CKD Hypertension

OBESITY PARADOX????!

Therapeutic perspectives

Obesity First line therapy Body weight reduction obesity - Calorie intake - Physical exercise Not effective in producing long term weight loss Second line therapy pharmacological treatment bariatric surgery (Bidani, 2013; Lambers Heerspink, 2012; XU, 2014)

Pharmacological treatments Retrieved from: http://www.google.fr/imgres?imgurl=http%3a%2f%2fupload.wikimedia.org

Thank you for your attention